SMAD3 and neoplasm: Evaluation in humanized mouse models further confirmed that CD11c overexpression in ESCC resulted in immune evasion, tumor metastasis, and resistance to anti-programmed death ligand 1 (PD-L1) therapy, but could be rescued by combined treatment with anti-phospho-SMAD3.